Astroglial Inhibition of NF-κB Does Not Ameliorate Disease Onset and Progression in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)

2011

Astroglial Inhibition of NF-κB in ALS Mice

Sample size: 22 publication 10 minutes Evidence: moderate

Author Information

Author(s): Crosio Claudia, Valle Cristiana, Casciati Arianna, Iaccarino Ciro, Carrì Maria Teresa

Primary Institution: Department of Physiological, Biochemical and Cell Science, University of Sassari, Sassari, Italy

Can inhibiting the NF-κB pathway in astrocytes improve the onset and progression of ALS in a mouse model?

Inhibiting NF-κB in astrocytes does not improve disease onset or progression in ALS mice.

Astrocytes play a critical role in ALS progression.
Blocking NF-κB did not improve motor neuron survival.
Double transgenic mice showed no difference in disease onset compared to single transgenic mice.

The study looked at whether blocking a specific pathway in brain cells could help mice with ALS, but it didn't make a difference.

The researchers created transgenic mice with inhibited NF-κB in astrocytes and crossed them with ALS model mice to study disease progression.

The study did not explore all potential compensatory pathways that may affect ALS progression.

Mice used were of the C57BL/6 genetic background.

p<0.05

p<0.05

Access the complete publication on the publisher's website